Cell and Gene
-
Cell and Gene, CMMI, Drug shortages, DTC, FDA, Pharmacy Benefit Managers, State-based Reform, Supply Chain, Utilization ManagementAMP is WAC — 04/24/26
Read more: AMP is WAC — 04/24/26Stick a fork in me, I am done with this week. It was a busy week and then you add in a chief of staff (Eddie, the dog) that would whine every 2 hours at night to go outside to deal with a stomach issue and I’m toast. On one hand, #grateful, but ready for…
-
Caught my eye, Cell and Gene, Drug Prices, DTC, Inflation Reduction Act, Medicare Part D, State-based Reform, UncategorizedAMP is WAC — 03/27/26
Read more: AMP is WAC — 03/27/26I’m supposed to be getting ready to take a few days off but I’m having trouble detaching. I’m so in the zone (and happy with it all) that the idea of stopping seems scary? Which absolutely means that I need to take a break, right?… No issue next week unless something big happens. Say Yes…
-
340B, Affordable Care Act, Alzheimer’s, Biosimilars, Cell and Gene, CMMI, FDA, Inflation Reduction Act, Medicare Part D, ObesityAMP is WAC — 03/13/26
Read more: AMP is WAC — 03/13/26The Bigger They Are, the Faster They Grow. A new white paper from Health Capital Group, sponsored by Johnson & Johnson, analyzed HRSA’s OPAIS database from 2017 through 2023 and found something many observers of the 340B program have suspected for years; size is the dominant variable. Hospitals in the top quartile by bed size…
-
AMP is WAC — 10/03/25
Read more: AMP is WAC — 10/03/25Round ’em up. The Presidential priorities that have everything and nothing to do with each other. This week has been a healthcare whirlwind. Here’s what I think you need to know * Most favored nation policy is still kicking around and the company announcements are interesting, but I want to poke around under the hood…
-
Affordable Care Act, Caught my eye, Cell and Gene, Employers, Inflation Reduction Act, Medicaid, Medicare NegotiationAMP is WAC — 8/22/25
Read more: AMP is WAC — 8/22/25Some weeks it feels like this newsletter writes itself. This is not one of those weeks. Onward. Caught my Eye Medicaid Math. Kaiser Family Foundation has a terrific visual of how the One Big Beautiful Bill will impact the uninsured rate by state. Employer Math. Employers are expecting a big jump in premiums (9%, 7.6%…
-
AMP is WAC — 7/18/25
Read more: AMP is WAC — 7/18/25I have a case of existential dread, and yet the world keeps spinning so let’s do this… Caught my Eye More Cowbell. Late last year I put out a report on biosimilars and it called out how the Inflation Reduction Act could hurt innovation and savings for biosimilars. Here is a report from Matrix Global…
-
Caught my eye — 5/09/25
Read more: Caught my eye — 5/09/25Direct Cost. I’ve written about the cuts from the National Institutes of Health (NIH), but I’m not sure I was clear on the impact on pharmaceutical manufacturers. Pharma relies on basic research for its drugs, and they also rely on scientists that have been trained in graduate schools and post-doctoral fellowships to develop and advance…
-
Affordable Care Act, Caught my eye, Cell and Gene, CMMI, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Pharmacy Benefit ManagersCaught my eye — 2/7/25
Read more: Caught my eye — 2/7/25In the DC area, with many family, friends and neighbors working for the federal government, these last few weeks have felt downright crappy. Furloughs, contracts being upended, fear about what’s next — all for people who love their jobs serving the public. It isn’t a fork in the road, it feels like a game of…
Latest news
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
- AMP is WAC — 03/20/26
- AMP is WAC — 03/13/26
Categories
- 340B (64)
- Affordable Care Act (23)
- Alzheimer's (11)
- Biosimilars (33)
- Caught my eye (102)
- Cell and Gene (8)
- Chevron Deference (2)
- CMMI (29)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (58)
- Drug shortages (15)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (13)
- Health Equity (4)
- Healthcare Costs (41)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (69)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (24)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (78)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (28)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (49)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (32)
- Supply Chain (8)
- Tariffs (2)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)